Special Issue "Treatment of Stroke, Dementia and Atrial Fibrillation"
Deadline for manuscript submissions: 5 August 2022.
Interests: cardiology; anticoagulants; antiplatelets; antithrombotics; electrophysiology; arrhythmias
Special Issues, Collections and Topics in MDPI journals
Interests: stroke; cerebrovascular events; silent stroke; dementia; mild cognitive impairment; anticoagulation; non vitamin k oral anticoagulants; atrial fibrillation; cardiac pacing
Stroke and dementia are among the top ten causes of death worldwide as estimated by the World Health Organization. Atrial fibrillation (AF) is estimated to cause of about 15 percent of all ischemic strokes and as many as 30 percent of strokes occurring in people in their 80s. The reduction of burden of stroke related to AF is a difficult goal to achieve because of a few clinical characteristics of AF itself: 1) episodes of arrhythmias may be asymptomatic and misdiagnosed, 2) stroke related to AF tends to be recurrent if an appropriate treatment is not promptly initiated, 3) the occurrence during AF of silent ischemic stroke that may not clinically manifest but may impact cognitive function. Indeed, silent ischemic cerebrovascular events have been recently proposed as the main pathophysiologic mechanisms linking AF with cognitive decline and dementia. 4) Finally, in AF the disjunction between the risks of cerebrovascular events (CVE) and the burden of arrhythmias is held as a dominant concept. Accordingly, the risk of CVE is not directly related to the presence of the arrhythmia but persists even during arrhythmia-free intervals. In other words, the two forms of AF classified according to duration (paroxysmal vs persistent) of arrhythmias hold the same risk of stroke.
Given the complexity of this topic and its impact on clinical practice and public health, Medicina is launching a Special Issue entitled “Stroke, Dementia and Atrial Fibrillation” with the aim of gathering together accurate and up-to-date scientific information on all aspects of association between cerebrovascular events, cognitive impairment and AF. We are pleased to invite you and your co-workers to submit your original research articles reporting on the pathophysiological mechanisms underpinning this association. We also encourage the submission of original manuscripts spanning basic to clinical research and focusing on stroke prevention in AF. We would also like to invite you to submit review articles aimed at providing a comprehensive overview of the recent advances in understanding pharmacological interventions to prevent CVE.
Prof. Dr. Vincenzo Russo
Prof. Dr. Riccardo Proietti
- Atrial Fibrillation
- Cognitive Impairment
- Oral anticoagulation
- Non vitamin K oral anticoagulants
- Cardiac implanted devices
- Neuromuscular Disorders